Rheumatoid Arthritis as a Therapeutic Challenge in a Patient with Lynch Syndrome

open access

  American Journal of Case Reports

Rheumatoid Arthritis as a Therapeutic Challenge in a Patient with Lynch Syndrome

Hossam Abdalla, Arindam Bagchi, Sabiha Bandagi

Am J Case Rep 2015; 16:390-392

DOI: 10.12659/AJCR.892906

..... With relation to RA treatment options, effectively decreasing systemic inflammation may in fact reduce the risk for cancer, but treatment of RA using the newer biologic agents like infliximab or adalimumab has been associated with increasedrisk of malignancy, specifically lymphoma [16,20,21].....

 

BACKGROUND: Lynch syndrome (LS) is an inherited colorectal cancer (CRC) syndrome accounting for about 3–5% of all cases and involves significantly higher risk of subsequent malignancies, colonic as well as extra-colonic. Increased risk of malignancies, especially lymphoid malignancies, have been described in patients with autoimmune diseases like rheumatoid arthritis (RA), systemic lupus erythematosus, and Sjögren’s syndrome. Epidemiological studies demonstrated that hematopoietic, lung, skin, and prostate cancers are increased in RA, while breast and colon cancers are decreased, with an overall slight increase in all cancers.

CASE REPORT: Our case demonstrates the development of CRC, endometrial cancer, and breast cancer as a presentation of LS in a patient with RA and presents a therapeutic challenge for RA treatment.

CONCLUSIONS: We describe a patient with LS and RA presenting a therapeutic challenge because biologic agents commonly used to treat severe RA need to be used cautiously in patients with history of malignancy.

Keywords: Arthritis, Rheumatoid, Biological Therapy, Lynch Syndrome II